The last day of trading in paid subscribed shares (BTAs) is 12 January 2021. BTAs will be converted to shares on 18 January 2021 and the ISIN code for the BTAs will be merged with the permanent ISIN code on 18 January 2021. The newly issued shares are expected to be delivered to the shareholders’ securities accounts on 18 January 2021.
Following registration of the new shares with the Danish Business Authority, the Company's share capital has increased by DKK 787,320.8280 to a total of DKK 2,361,962.4840. The number of shares and voting rights in the Company has increased by 10,711,848 shares and voting rights to a total of 32,135,544 shares and voting rights.
The updated articles of association of the Company are available on the Company's website, www.scandiononcology.com.
For further information, please contact:
Bo Rode Hansen, CEO
Phone: +45 38 10 20 17
The information was provided by the contact person above for publication on 6 January 2021.
About Scandion Oncology
Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Ticker code: SCOL